Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

Dr Scott Tagawa discusses how dose adjustments can optimize the use of enfortumab vedotin in urothelial cancer.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he brushed ...

NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...

Enfortumab vedotin is often combined with the immunotherapy drug pembrolizumab to treat advanced bladder cancer. While lifestyle changes can’t help treat bladder cancer, some adjustments can ...

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Bladder cancer leads to significant morbidity and ... multicenter phase 2 trial investigating enfortumab vedotin alone in patients with previously treated advanced solid tumors. This trial also has a ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

The company already has two other cancer drugs approved – Adcetris (brentuximab vedotin) for certain forms of lymphoma and Padcev (enfortumab vedotin) for advanced bladder cancer. The FDA had ...

Patients with advanced (muscle-invasive) bladder cancer had significantly less ... which include durvalumab and enfortumab vedotin combined with pembrolizumab, are presenting game-changing ...

It was there that a biopsy uncovered the truth: Armando had Stage 4 metastatic urothelial carcinoma (mUC), also known as advanced bladder ... Exploring PADCEV (enfortumab vedotin-ejfv) with ...